<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891498</url>
  </required_header>
  <id_info>
    <org_study_id>53</org_study_id>
    <nct_id>NCT03891498</nct_id>
  </id_info>
  <brief_title>The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia</brief_title>
  <official_title>The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      100 women with severe preeclanpsia received Magnesium sulfate 6 grams intravenous over 20
      minutes as a loading dose. Resistance index [RI], pulsatility index [PI] and
      systolic/diastolic [S/D] ratio of the umbilical artery, uterine aryery and fetal middle
      cerebral artery before and repeated 20 minutes after intravenous administration of 6 grams of
      magnesium sulphate (loading dose) over 20 minutes . fetal breathing movements and fetal gross
      movements are counted within 20 minutes, before and after intravenous administration of 6
      grams of magnesium sulphate (loading dose) over 20 minutes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 women with severe preeclanpsia received Magnesium sulfate 6 grams intravenous over 20
      minutes as a loading dose. Resistance index [RI], pulsatility index [PI] and
      systolic/diastolic [S/D] ratio of the umbilical artery, uterine aryery and fetal middle
      cerebral artery before and repeated 20 minutes after intravenous administration of 6 grams of
      magnesium sulphate (loading dose) over 20 minutes . fetal breathing movements and fetal gross
      movements are counted within 20 minutes, before and after intravenous administration of 6
      grams of magnesium sulphate (loading dose) over 20 minutes
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in uterine artery resistance index</measure>
    <time_frame>15 minutes after the loading dose of MgSO4</time_frame>
    <description>Doppler assessment of uterine artey RI</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>MgSO4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSO4</intervention_name>
    <description>The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.</description>
    <arm_group_label>MgSO4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy.

          -  Primigravida or Multigravida.

          -  Pregnant females ≥ 37 weeks of gestation.

          -  Diagnosed as severe preeclampsia by the following criteria:

               -  Sustained systolic blood pressure of ≥160 mmHg or a sustained diastolic blood
                  pressure of ≥ 110 mmHg.

               -  Proteinuria measured as +1 or more by dipstick or 24 hours urine collection with
                  proteinuria ≥ 0.3 grams.

               -  Oliguria or creatinine &gt; 1.1 mg%.

               -  Laboratory findings characteristic of HELLP syndrome.

               -  Symptoms suggestive of severe preeclampsia ; severe headache, blurring of vision,
                  epigastric pain.

        Exclusion Criteria:

          -  Multifetal pregnancy.

          -  History of epilepsy.

          -  Patients with diabetes.

          -  Patients with renal disease.

          -  Fetuses with congenital anomalies.

          -  Patients receiving anticoagulants e.g. heparin (unfractionated or low molecular
             weight).

          -  Patients with severe IUGR.

          -  Patients with accidental hemorrhage.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Maged, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Maged, MD</last_name>
    <phone>+201005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Elmahy, MD</last_name>
    <phone>01111831716</phone>
    <email>Mohamed.elmahy@kasralainy.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 24, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed M Maged, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

